Hallscheidt P, Besharati S, Noeldge G, Haferkamp A, Lopez R, Kauffmann G W
Abteilung Radiodiagnostik, Universitätsklinikum Heidelberg.
Rofo. 2006 Apr;178(4):391-9. doi: 10.1055/s-2006-926538.
To evaluate the influence of preoperative and palliative embolization of renal cell carcinomas on survival, intra- and post-operative procedures, and symptom control for palliative and preoperative indications.
56 patients who underwent renal cell carcinoma embolization from 1981 to 1999 were included in this retrospective study.
24 women and 32 men were included (mean age 59.4 years). Complete follow-up data was available for 49 patients. 42 patients underwent preoperative embolization at different tumor stages (pT1: 1 patient, pT2: 6, pT3 a: 4, pT3 b: 19, pT3 c: 2, pT4: 5). 14 patients underwent palliative embolization (T1: 0 patients, T2: 5, T3: 4, T4: 4). Indications for preoperative embolization were bleeding of the renal tumor in 6 cases -- non-recurrent bleeding reported, flank pain in 4 patients -- 3 of 4 patients had no further symptoms, recurrent tumor embolization in 1 patient, and 2 patients who wanted to be treated without symptoms. The mean survival time of preoperative embolized patients was 3.1 +/- 5.11 years with a 5-year survival rate of 50 %. The mean survival time of palliative embolized patients was 0.67 +/- 0.76 years with initial metastases (n = 7) and 2.33 +/- 2.40 without metastases (n = 6).
Palliative embolization of renal cell carcinomas is a safe therapeutic method to treat advanced renal cell carcinomas allowing control of symptoms such as hematuria and flank pain in more than 90 % of our cases. Preoperative embolization yields a patient survival time comparable to that of patients at earlier tumor stages and is dependent on the metastases.
评估肾细胞癌术前及姑息性栓塞对生存、手术中和手术后程序以及姑息性和术前适应证的症状控制的影响。
本回顾性研究纳入了1981年至1999年期间接受肾细胞癌栓塞治疗的56例患者。
纳入24名女性和32名男性（平均年龄59.4岁）。49例患者有完整的随访数据。42例患者在不同肿瘤分期接受了术前栓塞（pT1：1例，pT2：6例，pT3a：4例，pT3b：19例，pT3c：2例，pT4：5例）。14例患者接受了姑息性栓塞（T1：0例，T2：5例，T3：4例，T4：4例）。术前栓塞的适应证包括6例肾肿瘤出血——报告为非复发性出血，4例患者出现侧腹痛——4例患者中有3例无进一步症状，1例患者为复发性肿瘤栓塞，以及2例无症状但希望接受治疗的患者。术前栓塞患者的平均生存时间为3.1±5.11年，5年生存率为50%。有初始转移（n = 7）的姑息性栓塞患者的平均生存时间为0.67±0.76年，无转移（n = 6）的患者为2.33±2.40年。
肾细胞癌的姑息性栓塞是一种安全的治疗方法，可用于治疗晚期肾细胞癌，在我们超过90%的病例中可控制血尿和侧腹痛等症状。术前栓塞产生的患者生存时间与早期肿瘤分期患者相当，并且取决于转移情况。
